Zilucoplan: Physiology and What Research Reports
Zilucoplan is a synthetic macrocyclic peptide that blocks complement component 5 (C5), stopping membrane attack complex formation, and it is approved as a subcutaneous treatment for AChR antibody-positive generalised myasthenia gravis (PMID 38093160). The phase 3 RAISE trial reported greater reduction in myasthenia gravis symptom scores with 0.3 mg/kg daily subcutaneous zilucoplan than placebo over 12 weeks, with injection-site bruising among the most common events (PMID 37059508). A randomised trial in amyotrophic lateral sclerosis reported no benefit on disease progression (PMID 39960672).
What Zilucoplan Is
Zilucoplan is a chemically synthesised macrocyclic peptide that binds complement component 5 (C5). Researchers who published the discovery programme described it as a macrocyclic peptide C5 inhibitor developed for anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis (gMG) (discovery report, 2025). A first-approval review reported that zilucoplan was approved for adults with AChR antibody-positive gMG and is administered by subcutaneous injection rather than intravenous infusion (Drugs, 2024). It is a prescription medicine in the jurisdictions where it is approved, not a research-only compound, and this page summarises what the published literature reports about it. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question.
Where It Acts in the Body
Zilucoplan is not made in the body. It is a manufactured peptide that acts on a protein the liver produces: C5, a central component of the complement system. Complement is part of innate immunity and can be triggered by antibodies bound to tissue.
The terminal complement step
Once complement is activated, C5 is cleaved into C5a, an inflammatory signalling fragment, and C5b, which assembles with C6 through C9 into the membrane attack complex (MAC). In AChR antibody-positive gMG, antibodies at the neuromuscular junction recruit complement, and MAC formation damages the postsynaptic muscle membrane, reducing the efficiency of signal transmission and producing fatigable weakness. The discovery paper described zilucoplan as inhibiting this terminal step both by preventing C5 cleavage and by blocking C5b from engaging C6 (J Med Chem, 2025).
How Zilucoplan Is Measured and Studied
Because complement activity at the neuromuscular junction cannot be observed directly in patients, trials have relied on clinical rating scales plus safety monitoring. The phase 3 RAISE study measured change from baseline at week 12 in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score as its primary outcome, alongside the examiner-scored Quantitative Myasthenia Gravis (QMG) scale (Lancet Neurol, 2023). Earlier work in moderate-to-severe gMG used the same family of scales in a randomised, double-blind, placebo-controlled phase 2 design (JAMA Neurol, 2020). Longer-term questions have been approached through open-label extension follow-up and observational cohorts rather than continued placebo comparison.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Literature Reports in Generalised Myasthenia Gravis
| Study | Design | What was reported |
|---|---|---|
| Phase 2 | Randomised, double-blind, placebo-controlled | Researchers reported that self-administered subcutaneous zilucoplan 0.3 mg/kg daily produced statistically significant and clinically meaningful reductions in QMG and MG-ADL scores over 12 weeks, while 0.1 mg/kg daily produced smaller changes (JAMA Neurol, 2020) |
| RAISE (phase 3) | Randomised, double-blind, placebo-controlled | The study reported a greater reduction in MG-ADL and QMG scores at week 12 with subcutaneous zilucoplan 0.3 mg/kg daily than with placebo (Lancet Neurol, 2023) |
| RAISE subgroup | Prespecified subgroup of RAISE | Researchers reported efficacy in participants who had not previously received immunoglobulin or plasma exchange (J Neurol Sci, 2025) |
| RAISE-XT | Open-label extension, interim analysis | The interim analysis reported sustained improvements in myasthenia gravis outcome measures with long-term treatment and a safety profile consistent with the controlled studies (Ther Adv Neurol Disord, 2024) |
| Background therapy analysis | Analysis of long-term extension data | Researchers reported changes in corticosteroid and non-steroidal immunosuppressive therapy, including dose reductions, during long-term zilucoplan treatment (J Neurol, 2025) |
| Switch study | Phase IIIb, open-label | The study reported outcomes in patients switching from intravenous C5 inhibitors to subcutaneous zilucoplan (Ther Adv Neurol Disord, 2025) |
| ZILU25 | Multicentre observational cohort | Investigators reported early real-life experience with zilucoplan in generalised myasthenia gravis outside the trial setting (J Neurol Sci, 2025) |
What the Literature Reports Outside Myasthenia Gravis
Complement activation has been proposed as a contributor to other neurological diseases, which prompted testing beyond gMG. A randomised clinical trial in amyotrophic lateral sclerosis reported that zilucoplan did not improve measures of disease progression compared with placebo (JAMA Netw Open, 2025). That negative result is a useful reminder that a mechanism being biologically plausible in one disease does not transfer automatically to another.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appZilucoplan Safety and Adverse Events: What Studies Report
The phase 3 study reported that treatment-emergent adverse events occurred at broadly similar overall frequency in the zilucoplan and placebo groups, with injection-site bruising among the most commonly reported events (Lancet Neurol, 2023). The open-label extension interim analysis reported that the long-term safety profile remained consistent with the double-blind studies (Ther Adv Neurol Disord, 2024), and the earlier phase 2 trial reported that self-administered subcutaneous dosing was generally well tolerated in moderate-to-severe gMG (JAMA Neurol, 2020).
A class-level consideration follows from the mechanism itself: because MAC formation contributes to host defence against encapsulated bacteria such as Neisseria meningitidis, terminal complement inhibition raises infection risk, which is why the first-approval review described zilucoplan within the labelling framework used for approved C5 inhibitors (Drugs, 2024). Observational reporting continues to add to this picture, with early real-life data published for generalised myasthenia gravis cohorts (J Neurol Sci, 2025).
Why It Matters to Peptide Readers
Zilucoplan is frequently cited as an example of peptide drug design solving a problem antibodies had solved first. Its macrocyclic structure was engineered to engage a large protein target with high affinity while remaining small enough for subcutaneous self-administration, as described in the discovery report (J Med Chem, 2025). For readers who encounter the word "peptide" mainly in research-chemical contexts, it illustrates the other end of the spectrum: a synthetic peptide with phase 2 and phase 3 randomised evidence and a regulatory approval (Drugs, 2024).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeLimitations of the Evidence
- The pivotal placebo-controlled comparison in gMG ran for 12 weeks, so longer-term conclusions rest on open-label follow-up (Lancet Neurol, 2023).
- Extension data are uncontrolled, and the published analysis was an interim one (Ther Adv Neurol Disord, 2024).
- Subgroup and switch analyses answer narrower questions than the primary trials did (J Neurol Sci, 2025).
- Evidence is specific to AChR antibody-positive gMG; a randomised trial in amyotrophic lateral sclerosis reported no benefit (JAMA Netw Open, 2025).
References
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study (The Lancet Neurology, 2023)
- Zilucoplan: First Approval (Drugs, 2024)
- Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial (JAMA Network Open, 2025)
- Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study (Therapeutic Advances in Neurological Disorders, 2024)
- Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis (Journal of Neurology, 2025)
- Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study (Journal of the Neurological Sciences, 2025)
- Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (Journal of Medicinal Chemistry, 2025)
- Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study (Journal of the Neurological Sciences, 2025)
- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial (JAMA Neurology, 2020)
- Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study (Therapeutic Advances in Neurological Disorders, 2025)
Frequently asked questions
What is zilucoplan?▾
Zilucoplan is a synthetic macrocyclic peptide that inhibits complement component 5 (C5). The published discovery report described it as a C5 inhibitor developed for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis (PMID 41379101), and a first-approval review reported that it was approved for adults with that condition and given by subcutaneous injection (PMID 38093160).
What adverse events have studies reported with zilucoplan?▾
The phase 3 RAISE study reported that treatment-emergent adverse events occurred at broadly similar overall frequency with zilucoplan and placebo, with injection-site bruising among the most common events (PMID 37059508). The open-label extension interim analysis reported that the long-term safety profile stayed consistent with the controlled studies (PMID 38638673). Terminal complement inhibition also carries class-level infection considerations (PMID 38093160).
What did the phase 3 RAISE trial report?▾
RAISE was a randomised, double-blind, placebo-controlled phase 3 study in generalised myasthenia gravis. The study reported that subcutaneous zilucoplan 0.3 mg/kg once daily produced a greater reduction in Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis scores at week 12 than placebo (PMID 37059508). A subgroup analysis reported similar findings in patients without prior immunoglobulin or plasma exchange (PMID 40450840).
What has long-term follow-up reported?▾
Researchers published an interim analysis of the RAISE-XT open-label extension, which reported sustained improvements in myasthenia gravis outcome measures and a safety profile consistent with the double-blind trials (PMID 38638673). A related analysis reported changes in corticosteroid and non-steroidal immunosuppressive therapy, including dose reductions, during long-term zilucoplan treatment (PMID 40504283).
Did zilucoplan work in amyotrophic lateral sclerosis?▾
No. A randomised clinical trial in amyotrophic lateral sclerosis reported that zilucoplan did not improve measures of disease progression compared with placebo (PMID 39960672). The result illustrates that complement inhibition showing benefit in antibody-mediated neuromuscular disease (PMID 37059508) does not automatically transfer to other neurological conditions.
How was zilucoplan administered in the trials?▾
Trials used daily subcutaneous self-administration. The phase 2 study compared 0.1 mg/kg and 0.3 mg/kg daily with placebo over 12 weeks and reported the larger dose produced clinically meaningful reductions in Quantitative Myasthenia Gravis and MG-ADL scores (PMID 32065623), and the phase 3 study evaluated 0.3 mg/kg daily (PMID 37059508). This is study description, not guidance.
What is known about switching from intravenous C5 inhibitors?▾
A phase IIIb open-label study reported outcomes in patients with generalised myasthenia gravis who switched from intravenous complement component 5 inhibitors to subcutaneous zilucoplan (PMID 40620733). Separately, an early multicentre observational cohort, ZILU25, reported real-life experience with zilucoplan outside the randomised trial setting (PMID 41314023).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.